cardiotoxicity of cpx-351 vs 7 3 chemotherapy in patients with untreated high-risk aml
Published 1 year ago • 117 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
2:29
cpx-351 vs 7 3 in older high-risk aml patients
-
2:01
analyzing the cost-effectiveness of cpx-351 in patients with aml
-
2:11
cpx-351 plus venetoclax in patients with newly-diagnosed high-risk aml
-
3:07
improved understanding of cpx-351 in aml: impact of hct & final eap results
-
1:22
the benefit of cpx-351 over 7 3 in patients with saml by baseline bone marrow percentage
-
1:55
long-term real-world experience of cpx-351 in patients with t-aml and mrc-aml
-
1:12
cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
-
2:21
cpx-351 for high-risk aml
-
2:02
outcomes of cpx-352 vs. 7 3 for t-aml
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml
-
1:42
cpx-351 versus intensive induction chemo in pts with taml or aml with myelodysplasia-related changes
-
2:14
cpx-351: liposomal daunorubicin and cytarabine for treating high-risk aml
-
1:04
liposomal chemotherapy cpx-351: safety profile
-
3:48
cpx-351 for secondary aml: pharmacokinetics, administration & impact on treatment
-
2:16
cpx-351 in poor risk aml patients
-
1:30
evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml
-
4:01
aml-mrc: cpx-351 versus 7 3 therapy